P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY. (23rd June 2022) - Facon, T.; Kumar, S. K.; Plesner, T.; Moreau, P.; Bahlis, N.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Venner, C. P.; Weisel, K.; Mace, J. R.; Raje, N.; et al.